Stockreport

Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile [Yahoo! Finance]

Artelo Biosciences, Inc.  (ARTL) 
US:NASDAQ Investor Relations: artelobio.com/investors
PDF Phase 1 SAD Study Exhibited Excellent Safety with Zero Adverse Events Attributed to ART26.12 SOLANA BEACH, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Artelo Bioscienc [Read more]